Hormondiagnostik in der Peri- und Postmenopause – Schritt für Schritt

Die Lebensphase der Peri- und Postmenopause ist durch eine Reihe von klinischen Symptomen gekennzeichnet, die in individuell stark variierender Häufigkeit und Intensität auftreten. Die Hormondiagnostik in der Peri- und Postmenopause sollte jedoch auf ein Minimum an Laboranalysen beschränkt werden. Die aktuelle Leitlinie empfiehlt, dass die Peri- und Postmenopause bei Frauen > 45 Jahren mittels klinischer Parameter bestimmt werden soll.

Schlüsselwörter

Klimakterium - Hormonanalyse - Wechseljahre - Östradiol - Hormonersatztherapie

Publication History

Article published online:
15 August 2023

• Literatur

• 1 Baber R. The hot flush: symptom of menopause or sign of disease?. Climacteric 2017; 20: 291-292 DOI: 10.1080/13697137.2017.1342346. (PMID: 28699430)
• 2 Nelson HD, Haney E, Humphrey L. et al. Management of menopause-related symptoms. Evid Rep Technol Assess 2005; 120: 12 (PMID: 15910013)
• 3 Avis NE, Crawford SL, Greendale G. et al. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med 2015; 175: 531-539 DOI: 10.1001/jamainternmed.2014.8063. (PMID: 25686030)
• 4 Weidner K, Richter J, Bittner A. et al. Klimakterische Beschwerden über die Lebensspanne? Ergebnisse einer repräsentativen Umfrage in der deutschen Allgemeinbevölkerung. Psychother Psych Med 2012; 63: 266-275
• 5 FSRH. FSRH Guideline: Contraception for women aged over 40 years. 2017 Accessed April 26, 2023 at: http://www.fsrh.org/documents/fsrh-guidance-contraception-for-women-aged-over-40-years-2017/
• 6 DGGG, OEGGG, SGGG. S3-Leitlinie: Peri- und Postmenopause – Diagnostik und Interventionen. AWMF-Registernummer 015–062; Leitlinienklasse S3; Stand Januar 2020 inklusive Addendum September 2020; Version 1.1. Accessed April 26, 2023 at: www.awmf.org/uploads/tx_szleitlinien/015-062l_S3_HT_Peri-Postmenopause-Diagnostik-Interventionen_2021-01.pdf
• 7 Endokrinologikum–aesculabor Hamburg. Referenzwerte für die Hormonbestimmung. Accessed April 26, 2023 at: www.endokrinologikum-aesculabor.de/leistungsverzeichnis/hormone/parameter/estradiol.html
• 8 Randolph jr. JF, Zheng H, Sowers MR. et al. Change in follicle-stimulating hormone and estradiol across the menopausal transition: effect of age at the final menstrual period. J Clin Endocrinol Metab 2011; 96: 746-754
• 9 Sriprasert I, Kono N, Karim R. et al. Factors associated with serum estradiol levels among postmenopausal women using hormone therapy. Obstet Gynecol 2020; 136: 675-684
• 10 Guttmann H, Weiner Z, Nikolski E. et al. Choosing an oestrogen replacement therapy in young adult women with Turner syndrome. Clin Endocrinol 2001; 54: 159-164
• 11 Coulam CB, Adamson SC, Annegers JF. Incidence of premature ovarian failure. Obstet Gynecol 1986; 67: 604-606 (PMID: 3960433)
• 12 Langrish JP, Mills NL, Bath LE. et al. Cardiovascular effects of physiological and standard sex steroid replacement regimens in premature ovarian failure. Hypertension 2009; 53: 805-811 DOI: 10.1161/HYPERTENSIONAHA.108.126516. (PMID: 19332659)
• 13 Karim R, Xu W, Kono N. et al. Effect of menopausal hormone therapy on arterial wall echomorphology: results from the Early versus Late Intervention Trial with Estradiol (ELITE). Maturitas 2022; 162: 15-22
• 14 Sriprasert I, Hodis HN, Bernick B. et al. Effects of estradiol dose and serum estradiol levels on metabolic measures in early and late postmenopausal women in the REPLENISH trial. J Womens Health 2020; 29: 1052-1058 DOI: 10.1089/jwh.2019.8238. (PMID: 32644875)
• 15 Bromberger JT, Schott LL, Kravitz HM. et al. Longitudinal change in reproductive hormones and depressive symptoms across the menopausal transition: results from the study of women’s health across the nation (SWAN). Arch Gen Psychiatry 2010; 67: 598-607
• 16 Colvin A, Richardson GA, Cyranowski JM. et al. The role of family history of depression and the menopausal transition in the development of major depression in midlife women: study of women’s health across the nation mental health study (SWAN MHS). Depress Anxiety 2017; 34: 826-835 DOI: 10.1002/da.22651. (PMID: 28489293)
• 17 The North American Menopause Society. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause 2018; 25: 1362-1387 DOI: 10.1097/GME.0000000000001241. (PMID: 30358733)
• 18 Gordon JL, Rubinow DR, Eisenlohr-Moul TA. et al. Efficacy of transdermal estradiol and micronized progesterone in the prevention of depressive symptoms in the menopause transition: a randomized clinical trial. JAMA Psychiatry 2018; 75: 149-157 DOI: 10.1001/jamapsychiatry.2017.3998. (PMID: 29322164)